Renal failure associated with the use of celecoxib and rofecoxib

Drug Safety

Volumn 25, Issue 7, 2002, Pages 537-544

  Ahmad, Syed R ^a   Kortepeter, Cindy ^a   Brinker, Allen ^a   Chen, Min ^a   Beitz, Julie ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ADOLESCENT; ADULT; AGED; ARTICLE; DRUG SURVEILLANCE PROGRAM; FEMALE; HIGH RISK PATIENT; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYMPTOMATOLOGY;

EID: 0036316351     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200225070-00007     Document Type: Article

References (33)

1. Cyclooxygenase-2 enzyme inhibitors: Place in therapy
2. The coxibs, selective inhibitors of cyclooxygenase-2
3. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial
4. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
5. Celecoxib and rofecoxib
6. COX-2 and the kidneys
7. Effect of cyclo-oxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet: A randomized, controlled trial
8. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects
9. Effects of nonsteroidal anti-inflammatory drugs on renal function: Focus on cyclooxygenase-2-selective inhibition
10. Renal and cardiovascular effects of selective cyclooxygenase-2 inhibitors
11. The medical dictionary for regulatory activities (MedDRA)
12. Acute renal failure related to high-dose celecoxib
13. Acute tululointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib
14. Selective cyclooxygenase-2 inhibitors: A pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs
15. Rofecoxib-induced renal dysfunction in a patient with compensated cirrhosis and heart failure
16. Acute renal failure associated with rofecoxib
17. Are selective COX-2 inhibitors nephrotoxic?
18. COX-2 inhibitor acute renal failure: Association with hyperkalemia and type IV renal tubular acidosis
19. Celecoxib-induced acute renal failure
20. Celecoxib-induced nonoliguric acute renal failure
21. Celecoxib-induced acute interstitial nephritis
22. Rofecoxib (Vioxx): A year in review
23. Celecoxib (Celebrex): 1 year later
24. Celecoxib: Early Australian reporting experience
25. Rofecoxib (Vioxx)
26. Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons
27. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease
28. Nonsteroidal anti-inflammatory drug-associated azotemia in the very old
29. Renal aspects of treatment with conventional non-steroidal anti-inflammatory drugs versus cyclooxygenase-2-specific inhibitors
30. Nonsteroidal anti-inflammatory drug nephrotoxicity: Should we be concerned?
31. Nonsteroidal antiinflammatory drugs: Effects on kidney function
32. Are COX-2 selective inhibitors nephrotoxic
33. Cyclo-oxygenase-2 inhibitors and the kidney: A case for caution